To enable cancer researchers, ATCC (American Type Culture Collection) has introduced a collection of Tissue-Specific Tumor Cell Panels.
These new tools combine well-characterized adherent cell lines that were
selected for their genomic mutations as found in the Sanger COSMIC database,
greatly reducing the time and effort scientists devote to finding these
cells. Working closely with customers, ATCC scientists have identified cell
lines that that are easy to grow using standard media formulations and
possess critical genetic abnormalities found in tumors. Each Tissue-Specific
Tumor Cell Panel is comprised of different cell lines that have been grouped
by tissue of tumor origin. In developing the panels, ATCC scientists
evaluated 20 different genes associated with tumorigenesis, including TP53,
CDKN2A, BRAF, and KRAS. Descriptive information for each cell line has been
annotated with details regarding known mutations in these selected oncogenes
or receptors. Cell panels, as research models, are as valuable as the depth
of understanding and data supporting them. There are currently 10
Tissue-Specific Tumor Cell Panels in the collection, including panels for
breast cancer, triple-negative breast cancer, lung cancer, ovarian cancer,
colon cancer, liver cancer and pancreatic cancer.
Since 1925, ATCC has operated as an independent, non-profit entity that has
helped life science organizations and academic institutions produce
innovations that have benefited humankind: creating life saving vaccines,
nutritional improvements, cancer research breakthroughs, and safer, more
effective medications. With distribution to more than 140 countries and a
working relationship with 12 distribution partners, ATCC has the experience,
knowledge, rigor, tradition and the global reach to serve academic
institutions, government agencies, biotech, biopharma, and research
organizations around the world. ATCC is an ISO 9001:2008 certified, ISO/IEC
17025:2005, and ISO Guide 34:2009 accredited organization.